Accelerate Diagnostics, Inc.

Good day and welcome to the Accelerate Diagnostics Incorporated first quarter 2024 results conference call. All participants will be in a listen-only mode. After today's presentation, there will be an opportunity to ask questions with our covering analysts. I would now like to turn the conference over to Ms. Laura Pearson of Accelerate Diagnostics. Please go ahead, ma'am.

Before we begin, it is important to share that information presented during this call may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements include projections, statements about our future, and those that are not historical facts. All forward-looking statements are made during this conference call are subject to risk, uncertainties, and other factors that could cause our actual results to differ materially. These are discussed in greater detail in our annual report on Form 10-K for the year ended December 31, 2023, and other reports we file with the SEC. It is my pleasure to now introduce the company's president and CEO, Jack Phillips.

Thank you, Laura. Good afternoon. Today I would like to provide a detailed update on the WAVE program. Before I provide my update, I will pass it on to David Patience, our CFO, to summarize our financial results for the quarter.